Acrivon Competitors and Similar CompaniesClear all
Acrivon's competitors and similar companies include Iksuda Therapeutics, CARsgen Therapeutics, Numab and OncoTherapy Science.
 Acrivon Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline. |  Iksuda Therapeutics Iksuda is a biotechnology company that focuses on developing antibody-based therapies for the treatment of cancer. |  CARsgen Therapeutics CARsgen Therapeutics is a clinical-stage immune-oncology company that develops a new chimeric T-cell antigen receptor for liver, lung, stomach and brain cancers treatment. |  OncoTherapy Science OncoTherapy Science is a company engaged in research and development of cancer therapeutics. | ||
Founding Date | Founding Date 2018 | Founding Date 2007 | Founding Date 2014 | Founding Date 2011 | Founding Date 2001 |
Type | Type Public | Type Private | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations Watertown, US HQ Lund, SE | Locations Newcastle upon Tyne, GB HQ Newton, US | Locations Shanghai, CN HQ Beijing, CN Shanghai, CN Shanghai, CN Bellaire, US | Locations Wädenswil, CH HQ | Locations Kawasaki, JP HQ |
Employees | Employees 415% increase | Employees 43 | Employees 100 | Employees 681% decrease | Employees 54 |
Valuation ($) | Valuation ($) 256.1 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 56.9 m |
Financial | |||||
Net income | Net income ($77.9m) (FY, 2025) | Net income N/A | Net income N/A | Net income N/A | Net income (¥910.6m) (FY, 2026) |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 47m (almost 5 years ago) | Latest funding round $ 186m (over 5 years ago) | Latest funding round $ 110m (about 5 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised N/A | Total funding raised $ 47m | Total funding raised $ 276m | Total funding raised $ 132.3m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Iksuda Therapeutics
HQ
Newcastle upon Tyne, GB
Employees
43
Iksuda is a biotechnology company that focuses on developing antibody-based therapies for the treatment of cancer.
View companyCARsgen Therapeutics
HQ
Shanghai, CN
Employees
100
CARsgen Therapeutics is a clinical-stage immune-oncology company that develops a new chimeric T-cell antigen receptor for liver, lung, stomach and brain cancers treatment.
View company
Numab
HQ
Wädenswil, CH
Employees
68↓ 1% decrease
Numab Therapeutics is an oncology-focused biopharmaceutical company.
View companyOncoTherapy Science
HQ
Kawasaki, JP
Employees
54
OncoTherapy Science is a company engaged in research and development of cancer therapeutics.
View company